Prescription drug · NDA
Concerta (methylphenidate hydrochloride) NDC 50458-588
Methylphenidate hydrochloride 27 mg/1 · Tablet, Extended release · Oral · Janssen Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50458-588-01 | 50458058801 | 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (50458-588-01)Marketed from Aug 1, 2000 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Concerta
- Generic name (nonproprietary)
- methylphenidate hydrochloride
- Active ingredients
- Methylphenidate hydrochloride — 27 mg/1
- Dosage form
- Tablet, Extended release
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 021121
- Marketing start
- Listing expires
- DEA schedule
- CII
- Other FDA classes
- Central Nervous System Stimulation (Physiologic effect)
- Identifiers
- Product ID 50458-588_64d7c1e1-e7ed-4d74-a44d-13b4da64af9aSPL ID 64d7c1e1-e7ed-4d74-a44d-13b4da64af9aSPL set ID 1a88218c-5b18-4220-8f56-526de1a276cdRxCUI 1091155, 1091157, 1091170, 1091172, 1091185, 1091187, 1091210, 1091212UNII 4B3SC438HIUPC 0350458585018, 0350458587012, 0350458588019, 0350458586015
- Pharmacologic class
- Central Nervous System Stimulant
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N450458058801followed by a unit qualifier and the quantityPackage 50458-0588-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
CONCERTA is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 65 years old. Limitations of Use The use of CONCERTA is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.7) and Use in Specific Populations (8.4) ]. CONCERTA is a CNS stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 65 years old. ( 1 ) Limitations of Use The use of CONCERTA is not recommended in pediatric patients youn…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 021121
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Concertamethylphenidate hydrochloride | Methylphenidate hydrochloride 36 mg/1 | Tablet, Extended releaseOral | Janssen Pharmaceuticals, Inc. | 50458-586 |
| Concertamethylphenidate hydrochloride | Methylphenidate hydrochloride 18 mg/1 | Tablet, Extended releaseOral | Janssen Pharmaceuticals, Inc. | 50458-585 |
| Concertamethylphenidate hydrochloride | Methylphenidate hydrochloride 54 mg/1 | Tablet, Extended releaseOral | Janssen Pharmaceuticals, Inc. | 50458-587 |